Replies to post #605986 on NorthWest Biotherapeutics Inc (NWBO)

[EMHLondonUK]

Hoffmann,

The Forbes article, regrettably, feels mostly on the mark. I have never believed in huge amounts of naked shorting of the stock. On the margin? Yes. There’s enough FtDs and other things that on the margin there is some unhelpful stuff going on.

The reality is, our Enterprise Value (EV) is staying roughly constant as shares dilute and the negative Shareholders Equity account builds. It’s the nature of the funding mechanism management has used to get this treatment into approval.

So what turns the share price around and drives EV higher? In my view:
1. Material evidence in the 10-Q that specials demand is increasing and driving meaningful revenue
2. The MAA approval for marketing in the uk
3. FDA and/or NICE approval to drive health insurer / health system payor coverage of the treatment in SoC.

Those are really it. Everything else (including SPORE results) will be “scientific noise” in terms of the share price for the most part.

Once the three milestones are met above, it’ll find a new level - especially with an uplist and institutional buyers.

Anyway, I think we are getting there… but it’s taken us a long long time.

[biosectinvestor]

Excellent and contemporary Hoffmann and a relevant investor I believe.

[biosectinvestor]

Thankfully the lawsuit is not about "naked shorting", but about spoofing, which I always thought was a more likely case. Now, if they find naked shorting in the discovery, I would not be surprised. But they went with the best and most credible lawyers and we'll see. I believe Sabby has been around NWBO during different periods. Not sure if they claim to be a current investor or not, but I believe I have seen them around somewhere at some point. So I would not be surprised. It is just very difficult to prove something so many are so skeptical about. And as someone who knows the institutionalist view, people who work on WS basically presume it's a myth, even though firms do get prosecuted for it and it clearly exists. It's not supposed to exist, and in well-run organizations, I can tell you that the regulatory people presume there is no way it could occur in their organization so it must not exist. But we know otherwise.

They also prevent any trading in "penny stocks" at such organizations and I think the premise is, because shady stuff happens, but no one says what. And it's not the fault generally of the companies being traded, I think the reasons they don't do it is because perhaps even the organizations can't prevent their own people from doing shady stuff on the less regulated markets. The presumption is that it can't possibly happen on the regulated markets, but again, I think that is probably not entirely true, but just an ignorant presumption. The shady folks always seem to find a way to do what they want to do.

There are always hints that what happens is offshore funds, likely funded by dirty money, short these stocks to launder money, and that basically it is really bad people who do this stuff. People who are as close to money launderers and mafia as you can get on Wall Street. They can even basically trade with themselves in different countries, lose on one side and gain on the other, effectively laundering one currency into another. Some hedge funds that "do well" may even just be very sophisticated laundromats for dirty, foreign money or even domestic money that needs to get back to their home country. Like I said... very bad people.

It's why you'd put someone like Conrad Black on your board. The FBI is OK, but some of the former directors, multiple directors, basically have sold out to the Russian mob. William Sessions, worked for the head of the Russian Mob, Semion Mogilevich, when he left the FBI. His son, Pete, is in Congress now and likely continues in those duties. And of course, Louis Freeh, a familiar name.

https://www.businessinsider.com/fbi-director-louis-freeh-russia-prevezon-money-laundering-2017-11

https://washingtonmonthly.com/2018/09/17/the-shady-consultant-paying-guiliani-while-hes-white-house-counsel/